Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors

被引：4

作者：

Beck, Josephine ^{[1
]}

Guminski, Yves ^{[3
]}

Long, Christophe ^{[1
]}

Marcourt, Laurence ^{[1
]}

Derguini, Fadila ^{[1
]}

Plisson, Fabien ^{[1
]}

Grondin, Antonio ^{[2
]}

Vandenberghe, Isabelle ^{[2
]}

Vispe, Stephane ^{[2
]}

Brel, Viviane ^{[2
]}

Aussagues, Yannick ^{[1
]}

Ausseil, Frederic ^{[1
]}

Arimondo, Paola B. ^{[1
]}

Massiot, Georges ^{[1
]}

Sautel, Francois ^{[1
]}

Cantagrel, Frederic ^{[1
]}

机构：

[1] Ctr Rech & Dev Pierre Fabre, USR CNRS Pierre Fabre ETaC 3388, F-31035 Toulouse 01, France

[2] Ctr Rech & Dev Pierre Fabre, Ctr Rech Oncol Expt, Inst Rech Pierre Fabre, F-31035 Toulouse 01, France

[3] Ctr Rech Pierre Fabre, Div Chim Med, Inst Rech Pierre Fabre, F-81106 Castres, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2012年 / 20卷 / 02期

关键词：

Cycloartane; Neoboutonia melleri; Proteasome; Natural product; Anticancer agent; GROWTH-FACTOR SYNTHESIS; MULTIPLE-MYELOMA; FELLUTAMIDE-B; BIOLOGICAL-ACTIVITIES; STREPTOMYCES SP; IN-VITRO; BORTEZOMIB; POTENT; SALINOSPORAMIDE; LACTACYSTIN;

D O I：

10.1016/j.bmc.2011.11.066

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The interesting pharmacological properties of neoboutomellerones 1 and 2 were the basis for the assembly of a small library of analogues consisting of natural products isolated from the plant Neoboutonia melleri and of semisynthetic derivatives. As the two enone systems (C23-C24a and C1-C3) and the two hydroxyls groups (C22 and C26) of neoboutomellerones are required for activity, modifications were focused on these functional groups. Biological evaluation by using a cellular assay for proteasome activity provided clues regarding the mechanism of action of these natural products and synthetic derivatives. Certain neoboutomellerone derivatives inhibited the proliferation of human WM-266-4 melanoma tumor cells at submicromolar concentration and warrant evaluation as anticancer agents. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：819 / 831

页数：13

共 50 条

[1] The ubiquitin-proteasome pathway and proteasome inhibitors
Myung, J
Kim, KB
Crews, CM
[J]. MEDICINAL RESEARCH REVIEWS, 2001, 21 (04) : 245 - 273
[2] Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Schneekloth, John S., Jr.
Crews, Craig M.
[J]. CURRENT DRUG TARGETS, 2011, 12 (11) : 1581 - 1594
[3] Ubiquitin-proteasome pathway
Rivett, AJ
[J]. CURRENT PROTEIN & PEPTIDE SCIENCE, 2004, 5 (03)
[4] The ubiquitin-proteasome pathway
Roos-Mattjus, P
Sistonen, L
[J]. ANNALS OF MEDICINE, 2004, 36 (04) : 285 - 295
[5] Four New Carvotanacetone Derivatives from Sphaeranthus ukambensis, Inhibitors of the Ubiquitin-Proteasome Pathway
Pouny, Isabelle
Vispe, Stephane
Marcourt, Laurence
Long, Christophe
Vandenberghe, Isabelle
Aussagues, Yannick
Raux, Roselyne
Mutiso, Patrick B. Chalo
Massiot, Georges
Sautel, Francois
[J]. PLANTA MEDICA, 2011, 77 (14) : 1605 - 1609
[6] THE UBIQUITIN-PROTEASOME PROTEOLYTIC PATHWAY
CIECHANOVER, A
[J]. CELL, 1994, 79 (01) : 13 - 21
[7] The ubiquitin-proteasome pathway in cancer
V Spataro
C Norbury
AL Harris
[J]. British Journal of Cancer, 1998, 77 : 448 - 455
[8] The ubiquitin-proteasome pathway in cancer
Spataro, V
Norbury, C
Harris, AL
[J]. BRITISH JOURNAL OF CANCER, 1998, 77 (03) : 448 - 455
[9] Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system
Berndtsson, Maria
Beaujouin, Melanie
Rickardson, Linda
Havelka, Aleksandra Mandic
Larsson, Rolf
Westman, Jacob
Liaudet-Coopman, Emmanuelle
Linder, Stig
[J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (06) : 1463 - 1469
[10] Ubiquitin-Proteasome Pathway and Prostate Cancer
Chen, Fang-Zhi
Zhao, Xiao-Kun
[J]. ONKOLOGIE, 2013, 36 (10): : 592 - 596

← 1 2 3 4 5 →